Drugs / Recombinant Hepatitis B (Bio Farma)
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2/3 | NCT03919578 Comparator | Sep 2019 → Jan 2020 | — | PT Bio Farma | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Recombinant Hepatitis B (Bio Farma) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03919578 ↗ |
| Modality | Vaccine | “Recombinant Hepatitis B vaccine is an inactivated HbsAg produced in yeast cells (Hansenula polymorpha) using recombinant DNA technology.” NCT03919578 ↗ |